Cytalux

(Pafolacianine)

Cytalux

Drug updated on 1/4/2024

Dosage FormInjection (intravenous; 3.2 mg/1.6 mL (2 mg/mL))
Drug ClassOptical imaging agents
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated as an adjunct for intraoperative identification of malignant lesions in adult patients with ovarian cancer.
  • • Indicated as an adjunct for intraoperative identification of malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung.

Product Monograph / Prescribing Information

Document TitleYearSource
Cytalux (pafolacianine) Prescribing Information.2022On Target Laboratories, Inc., West Lafayette, IN

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Pafolacianine for intraoperative molecular imaging of cancer in the lung: The ELUCIDATE trial.
Data not availableSubjects
F: null%
M: null%
2023The Journal of Thoracic and Cardiovascular Surgery
A phase III study of pafolacianine injection (otl38) for intraoperative imaging of folate receptor–positive ovarian cancer (study 006).
Data not availableSubjects
F: null%
M: null%
2022Journal of Clinical Oncology

Sex Distribution:

NR

Year:

2023

Source:The Journal of Thoracic and Cardiovascular Surgery